Related Experiment Video
Updated: Mar 19, 2026
28:15
Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer
Published on: July 28, 2010
12.8K
Selenoprotein P in colitis-associated carcinoma
Sarah P Short1, Caitlyn Whitten-Barrett1, Christopher S Williams2
1Department of Medicine, Division of Gastroenterology, Vanderbilt University, Nashville, TN, USA; Department of Cancer Biology, Vanderbilt University, Nashville, TN, USA; Vanderbilt Ingram Cancer Center, Nashville, TN, USA.
Molecular & Cellular Oncology
|June 18, 2016
Summary
Inflammatory bowel disease patients with low selenium may face higher colon cancer risks. Reduced selenoprotein P (SEPP1) levels worsen this cancer risk and increase intestinal damage.
Area of Science:
- Biochemistry
- Oncology
- Gastroenterology
Background:
- Inflammatory bowel disease (IBD) is linked to micronutrient deficiencies, notably selenium.
- Patients with IBD have an elevated risk of developing colon cancer.
- The role of selenium transport proteins in IBD-associated tumorigenesis is not well understood.
Purpose of the Study:
- To investigate the impact of selenoprotein P (SEPP1) on colitis-associated cancer.
- To determine if SEPP1 deficiency influences tumor development and intestinal damage in the context of IBD.
Main Methods:
- Utilizing a mouse model of colitis-associated cancer.
- Examining the effects of global SEPP1 haploinsufficiency on tumorigenesis.
- Assessing markers of oxidative damage in the intestinal tissue.
Main Results:
- Global SEPP1 haploinsufficiency significantly augmented tumor development in the colitis-associated cancer model.
- Reduced SEPP1 levels were associated with increased oxidative damage in the intestine.
- These findings suggest a protective role for SEPP1 in preventing IBD-related colon cancer.
Conclusions:
- Selenoprotein P plays a crucial role in mitigating colitis-associated cancer.
- SEPP1 deficiency exacerbates intestinal oxidative stress and promotes tumorigenesis.
- Maintaining adequate selenium transport may be a therapeutic strategy for IBD patients at risk for colon cancer.
